UNSPSC 51432604: Monatepil

This classification denotes a calcium channel blocker with the molecular formula C28H30FN3OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, N4MMI0J7PW chemically known as 1-piperazinebutanamide, n-(6,11-dihydrodibenzo(b,e)thiepin-11-yl)-4-(4-fluorophenyl) but generally known as monatepil, which bears US NIH Compound Identifier 5282401. European Medicines Agency schedules Monatepil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09047MIG.

UNSPSC 51432604 Monatepil is a Commodity code encompassing prescription and over-the-counter medications that state and local governments procure for emergency medical services, institutional healthcare programs, and pharmacy benefit administration. State and local agencies soliciting under this code include municipal fire departments, state health and human services commissions, and multistate cooperative purchasing alliances serving state and local government facilities. The scope of recent activity spans emergency life support medications (epinephrine, adenosine, diltiazem, labetalol), generic multi-source pharmaceuticals, and OTC products distributed through established wholesale channels. Procuring bodies range from city purchasing departments managing single-jurisdiction emergency medical supply contracts to state-level health agencies and cooperative purchasing organizations coordinating multi-jurisdictional pharmaceutical procurement across dozens of participating municipalities and counties.

Activity concentrates in Florida and Minnesota with multistate implications. The City of Tampa Fire Rescue issued an IFB (Bid No. 26-P-00188) due April 8, 2026, with a contract value of $40,000 for advanced life support medications including specific quantities of four injectable drugs, with a Small Local Business Enterprise sheltered-market designation offering a 5 percent bid discount capped at $10,000. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (S1070000015802) due March 26, 2026, to establish multiple manufacturer contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers (Cencora, Cardinal Health, Morris & Dickson) across Minnesota, Oregon, and other participating jurisdictions, with awards effective July 1, 2026. The Texas Health and Human Services Commission posted an exploratory Request for Information (RFI No. HHS0017013) on March 27, 2026, seeking vendor capabilities for a direct-to-manufacturer prescription program outside traditional pharmacy benefit manager and group purchasing organization channels, signaling emerging state interest in alternative procurement models for pharmaceutical fulfillment.